Lipidomics as a tool for the study of lipoprotein metabolism

Current Atherosclerosis Reports

Volumn 12, Issue 3, 2010, Pages 194-201

  Kontush, Anatol ^a,b,c   Chapman, M John ^a,b,c  

^a SORBONNE UNIVERSITÉ   (France)

^b ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^c INSERM   (France)

Author keywords

HDL; LDL; Lipidome; Lipids; Lipoproteins; Plasma; VLDL

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPIDOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PROBIOTIC AGENT; ROSUVASTATIN; SIMVASTATIN; SPHINGOSINE 1 PHOSPHATE; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN;

APHERESIS; CARBOHYDRATE DIET; CARDIOVASCULAR DISEASE; COFFEE; CYSTIC FIBROSIS; DIET RESTRICTION; DRUG MEGADOSE; DYSLIPIDEMIA; FATTY LIVER; FISH; GENETIC ASSOCIATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIPID COMPOSITION; LIPIDOMICS; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN METABOLISM; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NONALCOHOLIC FATTY LIVER; OBESITY; PATHOPHYSIOLOGY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; THIN LAYER CHROMATOGRAPHY; WEIGHT REDUCTION; CARDIOVASCULAR DISEASES; METABOLISM; METABOLOMICS; MORBIDITY; PHYSIOLOGY; PROCEDURES; RISK FACTOR; TRENDS;

CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; HUMANS; LIPOPROTEINS; METABOLOMICS; MORBIDITY; RISK FACTORS;

EID: 77953545927     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0100-0     Document Type: Review

References (40)

1. Vaisar T: Thematic Review Series: Proteomics. Proteomic analysis of lipid-protein complexes. J Lipid Res 2009, 50:781-786.
2. Hoofnagle AN, Heinecke JW: Lipoproteomics: using mass spectrometry-based proteomics to explore the assembly, structure, and function of lipoproteins. J Lipid Res 2009, 50:1967-1975.
3. Davidsson P, Hulthe J, Fagerberg B, Camejo G: Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010, 30:156-163.
4. Oresic M, Hanninen VA, Vidal-Puig A: Lipidomics: a new window to biomedical frontiers. Trends Biotechnol 2008, 26:647-652.
5. Seppanen-Laakso T, Oresic M: How to study lipidomes. J Mol Endocrinol 2009, 42:185-190.
6. Wiesner P, Leidl K, Boettcher A, et al.: Lipid profiling of FPLCseparated lipoprotein fractions by electrospray ionization tandem mass spectrometry. J Lipid Res 2009, 50:574-585. This is a pioneering study of the lipidomics of isolated plasma lipoproteins (VLDL, LDL, HDL).
7. Sysi-Aho M, Vehtari A, Velagapudi VR, et al.: Exploring the lipoprotein composition using Bayesian regression on serum lipidomic profiles. Bioinformatics 2007, 23:i519-528.
8. Kontush A, Therond P, Zerrad A, et al.: Preferential sphingosine- 1-phosphate enrichment and sphingomyelin depletion are key features of small dense HDL3 particles: relevance to antiapoptotic and antioxidative activities. Arterioscler Thromb Vasc Biol 2007, 27:1843-1849. This is a pioneering study of the lipidome of isolated lipoprotein subclasses (HDL2b, 2a, 3a, 3b, 3c).
9. Hansel B, Giral P, Nobecourt E, et al.: Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J Clin Endocrinol Metab 2004, 89:4963-4971.
10. Kontush A, Chantepie S, Chapman MJ: Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. Arterioscler Thromb Vasc Biol 2003, 23:1881-1888.
11. Nilsson A, Duan RD: Absorption and lipoprotein transport of sphingomyelin. J Lipid Res 2006, 47:154-171.
12. Duong PT, Collins HL, Nickel M, et al.: Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I. J Lipid Res 2006, 47:832-843.
13. Nakamura Y, Kotite L, Gan Y, et al.: Molecular mechanism of reverse cholesterol transport: reaction of pre-beta-migrating highdensity lipoprotein with plasma lecithin/cholesterol acyltransferase. Biochemistry 2004, 43:14811-14820.
14. Subbaiah PV, Liu M: Role of sphingomyelin in the regulation of cholesterol esterification in the plasma lipoproteins. Inhibition of lecithin-cholesterol acyltransferase reaction. J Biol Chem 1993, 268:20156-20163.
15. Asztalos B, Zhang W, Roheim PS, Wong L: Role of free apolipoprotein A-I in cholesterol efflux. Formation of pre-alphamigrating high-density lipoprotein particles. Arterioscler Thromb Vasc Biol 1997, 17:1630-1636.
16. de Souza JA, Vindis C, Negre-Salvayre A, et al.: Small, dense HDL3 particles attenuates apoptosis in endothelial cells: pivotal role of apolipoprotein A-I. J Cell Mol Med 2009 (in press).
17. Catalano G, Julia Z, Frisdal E, et al.: Torcetrapib differentially modulates the biological activities of hdl2 and hdl3 particles in the reverse cholesterol transport pathway. Arterioscler Thromb Vasc Biol 2009, 29:268-275.
18. Zerrad-Saadi A, Therond P, Chantepie S, et al.: HDL3-mediated inactivation of LDL-associated phospholipid hydroperoxides is determined by the redox status of Apolipoprotein A-I and HDL particle surface lipid rigidity: relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2009, 29:2169-2175.
19. Taylor AJ, Villines TC, Stanek EJ, et al.: Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009, 361:2113-2122.
20. Kontush A, Guerin M, Chapman MJ: Spotlight on HDL-raising therapies: insights from the torcetrapib trials. Nat Clin Pract Cardiovasc Med 2008, 5:329-336.
21. Pietilainen KH, Sysi-Aho M, Rissanen A, et al.: Acquired obesity is associated with changes in the serum lipidomic profile independent of genetic effects-A monozygotic twin study. PLoS One 2007, 2:e218. This is an elegant demonstration of specific alterations in the serum lipidome in acquired obesity.
22. de Mello VD, Lankinen M, Schwab U, et al.: Link between plasma ceramides, inflammation and insulin resistance: association with serum IL-6 concentration in patients with coronary heart disease. Diabetologia 2009, 52:2612-2615.
23. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al.: Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum. Obesity (Silver Spring) 2009 (in press).
24. Kotronen A, Velagapudi VR, Yetukuri L, et al.: Serum saturated fatty acids containing triacylglycerols are better markers of insulin resistance than total serum triacylglycerol concentrations. Diabetologia 2009, 52:684-690. This is an excellent lipidomics-based detailing of the relationship between insulin resistance and circulating TG levels.
25. Puri P, Wiest MM, Cheung O, et al.: The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 2009, 50:1827-1838.
26. Kotronen A, Seppanen-Laakso T, Westerbacka J, et al.: Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver. Diabetes 2009, 58:203-208.
27. Kolak M, Westerbacka J, Velagapudi VR, et al.: Adipose tissue inflammation and increased ceramide content characterize subjects with high liver fat content independent of obesity. Diabetes 2007, 56:1960-1968.
28. Yetukuri L, Katajamaa M, Medina-Gomez G, et al.: Bioinformatics strategies for lipidomics analysis: characterization of obesity related hepatic steatosis. BMC Syst Biol 2007, 1:12.
29. Graessler J, Schwudke D, Schwarz PE, Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients. PLoS One 2009, 4:e6261. This is the first demonstration of abnormalities in the plasma lipidome in hypertension.
30. Guerrera IC, Astarita G, Jais JP, et al.: A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients. PLoS One 2009, 4:e7735. This is the first demonstration of abnormalities in the plasma lipidome in cystic fibrosis.
31. Schwab U, Seppanen-Laakso T, Yetukuri L, et al.: Triacylglycerol fatty acid composition in diet-induced weight loss in subjects with abnormal glucose metabolism-the GENOBIN study. PLoS One 2008, 3:e2630.
32. Lankinen M, Schwab U, Erkkila A, et al.: Fatty fish intake decreases lipids related to inflammation and insulin signaling-a lipidomics approach. PLoS One 2009, 4:e5258.
33. Lankinen M, Schwab U, Gopalacharyulu PV, et al.: Dietary carbohydrate modification alters serum metabolic profiles in individuals with the metabolic syndrome. Nutr Metab Cardiovasc Dis 2009 (in press).
34. Kekkonen RA, Sysi-Aho M, Seppanen-Laakso T, et al.: Effect of probiotic Lactobacillus rhamnosus GG intervention on global serum lipidomic profiles in healthy adults. World J Gastroenterol 2008, 14:3188-3194.
35. Altmaier E, Kastenmuller G, Romisch-Margl W, et al.: Variation in the human lipidome associated with coffee consumption as revealed by quantitative targeted metabolomics. Mol Nutr Food Res 2009, 53:1357-1365.
36. Bergheanu SC, Reijmers T, Zwinderman AH, et al.: Lipidomic approach to evaluate rosuvastatin and atorvastatin at various dosages: investigating differential effects among statins. Curr Med Res Opin 2008, 24:2477-2487. This is a pioneering study of the differential effects of rosuvastatin and atorvastatin on the plasma lipidome, notably on the SM/(SM+PC) ratio.
37. Jiang XC, Paultre F, Pearson TA, et al.: Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol 2000, 20:2614-2618.
38. Laaksonen R, Katajamaa M, Paiva H, et al.: A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PLoS One 2006, 1:e97.
39. Laaksonen R, Janis MT, Oresic M: Lipidomics-based safety biomarkers for lipid-lowering treatments. Angiology 2008, 59(2 Suppl):65S-68S.
40. Tselmin S, Schmitz G, Julius U, et al.: Acute effects of lipid apheresis on human serum lipidome. Atheroscler Suppl 2009, 10:27.